OR27-03 Oral Infigratinib Treatment Is Well Tolerated And Significantly Increases Height Velocity In Children With Achondroplasia: Month 6 Results From The PROPEL 2 Dose-finding Study

Disclosure: R. Savarirayan: Advisory Board Member; Self; Ascendis Pharma, BioMarin, QED Therapeutics, Sanofi. Consulting Fee; Self; BioMarin. Grant Recipient; Self; Ascendis Pharma, BioMarin, QED Therapeutics, Theracon. Research Investigator; Self; Ascendis Pharma, BioMarin, QED Therapeutics, Therac...

Descripción completa

Detalles Bibliográficos
Autores principales: Savarirayan, Ravi, De Bergua, Josep Maria, Arundel, Paul, Salles, Jean Pierre, Saraff, Vrinda, Delgado, Borja, Leiva-Gea, Antonio, McDevitt, Helen, Nicolino, Marc P, Rossi, Massimiliano, Salcedo, Maria, Cormier-Daire, Valerie, Skae, Mars, Kannu, Peter, Bober, Michael B, Phillips, John, Saal, Howard, Harmatz, Paul, Burren, Christine Pamela, Candler, Toby, Cho, Terry, Muslimova, Elena, Weng, Richard, Raj, Supriya, Hoover-Fong, Julie, Irving, Melita, Rogoff, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Pediatric Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555019/
http://dx.doi.org/10.1210/jendso/bvad114.1525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555019/
http://dx.doi.org/10.1210/jendso/bvad114.1525

Ejemplares similares